Table of Contents
Pramlintide Acetate Safety Review Dragos Roman MD
Pramlintide Acetate Safety Review Outline
Pramlintide Acetate Safety Review Outline
Phase 3 Clinical Trials
Phase 3 Clinical Trials (Type 1 Diabetes)
First Month Nausea-Related Withdrawals -Type 1 Diabetes
Phase 3 Clinical Trials (Type 2 Diabetes)
First Month Nausea-Related Withdrawals -Type 2 Diabetes
Pramlintide Acetate-Safety Review Outline
Assisted Hypoglycemia: Definition
Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: First Month Incidence
Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: End of the First Month to The End of the Trial Incidence
Change in HbA1c: Study 137-121 Type 1 Diabetes
Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: Summary
Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: Summary
Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: First Month Incidence
Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: End of the First Month to The End of the Trial Incidence
Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: Summary
Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: Summary
Assisted Hypoglycemia: Summary
Pramlintide Acetate Safety Review Outline
Serious Adverse Events-Definition
Deaths Possibly Related to Hypoglycemia
Pramlintide Acetate Safety Review Outline
Hypoglycemia and Accidents-Type 1 Diabetes
MVAs and Automobile-Related Adverse Events-Type 1 Diabetes (All Clinical Development Program)
Driving-Related Events Associated With Hypoglycemia -Phase 3 Trials (Type 1 Diabetes)
Driving-Related Events Associated With Hypoglycemia - Type 1 Diabetes: Conclusion
Other Accidents and Injuries-Type 1 Diabetes (All Clinical Development Program)
Other Accidents and Injuries-Phase 3 Trials (Type 1 Diabetes)
Other Accidents and Injuries- Type 1 Diabetes: Conclusion
Severe Hypoglycemia: Labeling Question
Severe Hypoglycemia: Labeling Question
Severe Hypoglycemia: Labeling Question
Accidents Associated With Hypoglycemia-Labeling Question
PPT Slide
Summary
|